U.S. markets closed

New Healthcare Trends Pushing Stocks Higher On Thursday

CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry will be one of the key sectors pushing unified communications and collaboration market growth, which is forecast to increase at a 9% CAGR and reach $57 billion by the end of 2024. These unified communications integrate various healthcare services into a single platform, helping companies to minimize service as well as hardware costs and improve worker productivity. These services include email, voice, instant messaging, desktop sharing, presence, and audio and video conferencing.

Heatlhcare stocks to watch: Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Auris Medical Holding AG (EARS), Daré Bioscience, Inc. (DARE), and Avinger, Inc. (AVGR)

Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI)'s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and has plans to rapidly increase that number both domestically and internationally. This is in line with the latest trend that's been growing within healthcare targeting new connected technology.

Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) announced this quarter that it will be planning on rolling out new initiatives. This includes entering the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019, as a part of its expansion plans.

Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) has also recently engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education. Furthermore, the Company is actively recruiting additional physicians for its existing clinics and a cannabis focused physician that is licensed in Canada.

This move could prove to be and exciting one for Premier. The Canadian medical cannabis clinic market is estimated to be worth approximately $2.35 billion by 2025. With this in mind, the company said that it expects to provide additional updates on acquisitions in Q4-18 and Q1-19.

For More Information On Premier Health Group, Click Here

Auris Medical Holding AG (EARS) is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care. Today the company announced a strategic expansion for its intranasal betahistine development program. In two related transactions, the Company has acquired an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS) and signed a binding letter of intent to in-license exclusive rights to two US Patents relating to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD), respectively.

"We are very excited to address additional neurological and metabolic disorders with our intranasal betahistine program," commented Thomas Meyer, Auris Medical's founder, Chairman and CEO.

The two transactions are expected to close before year-end and to have no impact on the Company's development plans or financial position in the near-term. As previously announced, the Company prepares for the initiation of two proof-of-concept studies with intranasal betahistine in the first quarter of 2019 - one Phase 2 trial with AM-125 in vertigo and one Phase 1b trial with AM-201 in antipsychotic-induced weight gain.

Shares of Auris were up as high as $0.72 during premarket trading on Thursday.

For More Information On Auris, Click Here

Shares of Daré Bioscience, Inc. (DARE) were off and running on Thursday, following the mid week pause in US markets on Wednesday. The company works with treatments designed for clinical-stage women's health innovation. Today Daré announced that it has entered into definitive agreements with Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC under which Daré acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans.

''We believe this Phase III program will allow us to move into a leadership position in an area of great concern for both women and healthcare providers,'' said Sabrina Martucci Johnson, President and CEO of Daré. ''Studies suggest that nearly 20 million women in the U.S. experience BV and many suffer from episodes of recurrence.''

For More Information On Daré Click Here

Avinger, Inc. (AVGR) also saw its share price rally. The company is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease. Today Avinger announced the commercial launch of its Pantheris image-guided atherectomy system in Australia. Avinger recently completed an exclusive distribution agreement with Diverse Devices Pty Ltd. for the sales and marketing of Avinger's proprietary Lumivascular products in Australia. In addition, the Company announced it has received notice from Australia's Therapeutic Goods Administration (TGA) that the Pantheris image-guided atherectomy system has been included on the Australian Register of Therapeutic Goods, which permits distribution in Australia.

Dr. Puttaswamy, the first operator to use image-guided atherectomy in Australia noted, ''Maximizing the channel for blood flow in revascularizing the vessel, while simultaneously minimizing vascular injury is the goal in treating patients with PAD. This new device provides another option for Australian clinicians when treating patients with this serious disease.''

Over the last few days, Avinger shares have moved from lows of $0.2947 to highs of $0.397

For More Information On Avinger, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Contact Information:


SOURCE: StockPrice.com